{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:04:38Z","timestamp":1770483878610,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the ongoing opioid crisis, regulatory restrictions on fentanyl and its derivatives have led to the emergence of nitazenes, a class of highly potent synthetic opioids synthesised during the 1950s but never approved for medical use. Structurally distinct from traditional opioids, nitazenes have gained increasing presence in illicit drug markets since 2019, contributing to a growing number of drug-related deaths across Europe, North America, and Australia. The rapid proliferation of novel nitazene analogues presents a significant challenge to law enforcement and public health systems. Drug-checking services (DCS) are currently one of the most effective tool for early detection and response, enabling real-time surveillance and consequently reducing the impact of overdoses due to Novel Synthetic Opioids. As a complement, universities can provide the scientific expertise and infrastructure necessary to confirm molecules detected by DCS. This study is the first report identifying and confirming 5-cyano isotodesnitazene in a street-sold drug, through an international collaboration involving two DCSs and three academic institutions. The structural elucidation was achieved through complementary analytical techniques comprising gas chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. The present work highlights the essential role that cross-sector cooperation and analytical innovation play in tackling the rapidly evolving threat of novel synthetic opioids.<\/jats:p>","DOI":"10.1038\/s41598-026-35256-4","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:55:54Z","timestamp":1768334154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Collaborative harm reduction efforts lead to the first detection of 5-cyano isotodesnitazene in illicit street drugs"],"prefix":"10.1038","volume":"16","author":[{"given":"B\u00e1rbara F. C.","family":"Barra","sequence":"first","affiliation":[]},{"given":"Joana R. P.","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Daniela R.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Hans","family":"Oeri","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Rui M.","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Giles","family":"Oatley","sequence":"additional","affiliation":[]},{"given":"Nuno R.","family":"Neng","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Gaspar","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Quintas","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"35256_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/BF02161116","volume":"13","author":"A Hunger","year":"1957","unstructured":"Hunger, A., Kebrle, J., Rossi, A. & Hoffmann, K. Synthese basisch substituierter, analgetisch wirksamer Benzimidazol-Derivate [Synthesis of analgesically active benzimidazole derivatives with basic substitutions]. Experientia 13, 400\u2013401 (1957).","journal-title":"Experientia"},{"key":"35256_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/BF02161117","volume":"13","author":"F Gross","year":"1957","unstructured":"Gross, F. & Turrian, H. Uber benzimidazolderivate Mit Starker analgetischer wirkung [Benzimidazole derivatives with strong analgesic effects]. Experientia 13, 401\u2013403 (1957).","journal-title":"Experientia"},{"key":"35256_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/BF01486702","volume":"36","author":"G Broming","year":"1958","unstructured":"Broming, G. Uber neue starkwirkende analgetika und Ihre klinische erprobung [New powerful analgetics and their clinical testing]. Klinische Wochenschrift. 36, 960\u2013963 (1958).","journal-title":"Klinische Wochenschrift"},{"key":"35256_CR4","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.3390\/molecules30193890","volume":"30","author":"JRP Pereira","year":"2025","unstructured":"Pereira, J. R. P., Quintas, A., Neng, N. R. & Nitazenes The emergence of a potent synthetic opioid threat. Molecules 30, 3890 (2025).","journal-title":"Molecules"},{"key":"35256_CR5","unstructured":"United Nations Office on Drugs and Crime. UNODC Early Warning Advisory (EWA) on New Psychoactive Substances (NPS). at https:\/\/www.unodc.org\/LSS\/Home\/NPS"},{"key":"35256_CR6","unstructured":"European Monitoring Centre for Drugs and Drug Addiction & & Europol EU Drug Market: New psychoactive substances \u2014 In-depth analysis. at (2024). https:\/\/www.euda.europa.eu\/publications\/eu-drug-markets\/new-psychoactive-substances_en#source-data"},{"key":"35256_CR7","unstructured":"United Nations Office on Drugs and Crime. International Drug Control Conventions. at https:\/\/www.unodc.org\/unodc\/en\/commissions\/CND\/Mandate_Functions\/Scheduling.html"},{"key":"35256_CR8","unstructured":"World Health Organization & rd Expert Committee on Drug Dependence. Critical Review Report: ISOTONITAZENE. (43 at (2020). https:\/\/cdn.who.int\/media\/docs\/default-source\/controlled-substances\/43rd-ecdd\/isonitazene-43rd-final-complete-a.pdf"},{"key":"35256_CR9","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Isotonitazene - EMCDDA initial report on the new psychoactive substance N,N-diethyl-2-4-(1-methylethoxy)phenylmethyl-5-nitro- 1H-benzimidazole-1-ethanamine (isotonitazene). Publications Office of the European Union. at https:\/\/data.europa.eu\/doi\/10.2810\/370922 (2020)."},{"key":"35256_CR10","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S2468-2667(24)00024-0","volume":"9","author":"I Giraudon","year":"2024","unstructured":"Giraudon, I., Abel-Ollo, K., Vanaga-Ar\u0101ja, D., Heudtlass, P. & Griffiths, P. Nitazenes represent a growing threat to public health in Europe. Lancet Public. Health. 9, e216 (2024).","journal-title":"Lancet Public. Health"},{"key":"35256_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-025-36425-0","author":"EL Keller","year":"2025","unstructured":"Keller, E. L., Peake, B., Simpson, B. S., White, J. M. & Gerber, C. Comprehensive method to detect nitazene analogues and xylazine in wastewater. Environ. Sci. Pollut Res. https:\/\/doi.org\/10.1007\/s11356-025-36425-0 (2025).","journal-title":"Environ. Sci. Pollut Res."},{"key":"35256_CR12","doi-asserted-by":"publisher","first-page":"170781","DOI":"10.1016\/j.scitotenv.2024.170781","volume":"920","author":"R Bade","year":"2024","unstructured":"Bade, R. et al. Wastewater-based monitoring of the nitazene analogues: first detection of protonitazene in wastewater. Sci. Total Environ. 920, 170781 (2024).","journal-title":"Sci. Total Environ."},{"key":"35256_CR13","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/add.70027","volume":"120","author":"R Bade","year":"2025","unstructured":"Bade, R. et al. Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: two years of data from 22 countries. Addiction 120, 1739\u20131746 (2025).","journal-title":"Addiction"},{"key":"35256_CR14","first-page":"100375","volume":"10","author":"D Gon\u00e7alves","year":"2024","unstructured":"Gon\u00e7alves, D. et al. Synthetic illicit opioids in brazil: nitazenes arrival. Forensic Sci. International: Rep. 10, 100375 (2024).","journal-title":"Forensic Sci. International: Rep."},{"key":"35256_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13033-023-00601-x","volume":"17","author":"M Meyer","year":"2023","unstructured":"Meyer, M. et al. Shifting drug markets in North America - a global crisis in the making? Int. J. Ment Health Syst. 17, 36 (2023).","journal-title":"Int. J. Ment Health Syst."},{"key":"35256_CR16","doi-asserted-by":"publisher","unstructured":"Mammoliti, E., Nielsen, S. & Roxburgh, A. A scoping review of the emergence of novel synthetic opioids in Australian drug markets: what does this mean for harm reduction responses? Drug Alcohol Rev. dar.14079 https:\/\/doi.org\/10.1111\/dar.14079 (2025).","DOI":"10.1111\/dar.14079"},{"key":"35256_CR17","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1111\/add.16525","volume":"119","author":"N Killeen","year":"2024","unstructured":"Killeen, N. et al. The emergence of nitazenes on the Irish heroin market and National Preparation for possible future outbreaks. Addiction 119, 1657\u20131658 (2024).","journal-title":"Addiction"},{"key":"35256_CR18","doi-asserted-by":"publisher","unstructured":"Nahar, L. K., Andrews, R. & Paterson, S. Deadly nitazenes: a 2024 update. BMJ q2614 https:\/\/doi.org\/10.1136\/bmj.q2614 (2024).","DOI":"10.1136\/bmj.q2614"},{"key":"35256_CR19","unstructured":"National Institute on Drug Abuse. Drug Overdose Deaths: Facts and Figures | National Institute on Drug Abuse (NIDA). at (2024). https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"},{"key":"35256_CR20","doi-asserted-by":"publisher","unstructured":"Isoardi, K. Z. et al. Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems. Drug and Alcohol Review dar.13998 (2025). https:\/\/doi.org\/10.1111\/dar.13998","DOI":"10.1111\/dar.13998"},{"key":"35256_CR21","unstructured":"World Health Organization. Expert Committee on Addiction-Producing Drugs [\u200emeeting held in Geneva from 10 to 15 October 1960]\u200e: eleventh report. at (1961). https:\/\/iris.who.int\/handle\/10665\/40481"},{"key":"35256_CR22","unstructured":"European Union Drugs Agency. European Drug Report 2025: Trends and developments. at (2025). https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025_en"},{"key":"35256_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/PAF.0000000000000787","volume":"43","author":"DM Papsun","year":"2022","unstructured":"Papsun, D. M., Krotulski, A. J. & Logan, B. K. Proliferation of novel synthetic opioids in postmortem investigations after Core-Structure scheduling for Fentanyl-Related substances. Am. J. Forensic. Med. Pathol. 43, 315\u2013327 (2022).","journal-title":"Am. J. Forensic. Med. Pathol."},{"key":"35256_CR24","first-page":"16","volume":"24","author":"United Nations Office on Drugs and Crime","year":"2020","unstructured":"United Nations Office on Drugs and Crime. The growing complexity of the opioid crisis. Global SMART Update. 24, 16 (2020).","journal-title":"Global SMART Update"},{"key":"35256_CR25","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/add.16420","volume":"119","author":"PN Griffiths","year":"2024","unstructured":"Griffiths, P. N., Seyler, T., De Morais, J. M., Mounteney, J. E. & Sedefov, R. S. Opioid problems are changing in Europe with worrying signals that synthetic opioids May play a more significant role in the future. Addiction 119, 1334\u20131336 (2024).","journal-title":"Addiction"},{"key":"35256_CR26","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1021\/acschemneuro.1c00037","volume":"12","author":"I Ujv\u00e1ry","year":"2021","unstructured":"Ujv\u00e1ry, I. et al. DARK classics in chemical neuroscience: Etonitazene and related benzimidazoles. ACS Chem. Neurosci. 12, 1072\u20131092 (2021).","journal-title":"ACS Chem. Neurosci."},{"key":"35256_CR27","unstructured":"United Nations Office on Drugs and Crime. Curr. NPS Threats 4, (2021)."},{"key":"35256_CR28","unstructured":"United States Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I. at (2022). https:\/\/www.federalregister.gov\/documents\/2022\/04\/12\/2022-07640\/schedules-of-controlled-substances-temporary-placement-of-butonitazene-etodesnitazene-flunitazene"},{"key":"35256_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12954-024-01014-w","volume":"21","author":"L Moran","year":"2024","unstructured":"Moran, L. et al. How do we understand the value of drug checking as a component of harm reduction services? A qualitative exploration of client and provider perspectives. Harm Reduct. J. 21, 92 (2024).","journal-title":"Harm Reduct. J."},{"key":"35256_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12954-024-01078-8","volume":"21","author":"LM De Vrieze","year":"2024","unstructured":"De Vrieze, L. M., Stove, C. P. & Vandeputte, M. M. Nitazene test strips: a laboratory evaluation. Harm Reduct. J. 21, 159 (2024).","journal-title":"Harm Reduct. J."},{"key":"35256_CR31","doi-asserted-by":"publisher","unstructured":"Curtis, B., Lawes, D., Caldicott, D. & McLeod, M. D. Identification of the novel synthetic opioid N-pyrrolidino isotonitazene at an Australian drug checking service. (2024). https:\/\/doi.org\/10.26434\/chemrxiv-2024-0mdvs","DOI":"10.26434\/chemrxiv-2024-0mdvs"},{"key":"35256_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12954-023-00924-5","volume":"21","author":"KJ Moon","year":"2024","unstructured":"Moon, K. J. et al. Enhancing drug checking services for supply monitoring: perspectives on implementation in syringe service programs in the USA. Harm Reduct. J. 21, 11 (2024).","journal-title":"Harm Reduct. J."},{"key":"35256_CR33","doi-asserted-by":"publisher","first-page":"100605","DOI":"10.1016\/j.forc.2024.100605","volume":"40","author":"EK Hardwick","year":"2024","unstructured":"Hardwick, E. K. & Davidson, J. Structural characterization of nitazene analogs using electron ionization-mass spectrometry (EI-MS). Forensic Chem. 40, 100605 (2024).","journal-title":"Forensic Chem."},{"key":"35256_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3921","author":"EK Hardwick","year":"2025","unstructured":"Hardwick, E. K. & Davidson, J. Structural characterization of nitazene analogs using electrospray Ionization-Tandem mass spectrometry (ESI-MS\/MS). Drug. Test. Anal. https:\/\/doi.org\/10.1002\/dta.3921 (2025).","journal-title":"Drug. Test. Anal."},{"key":"35256_CR35","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","volume":"12","author":"MM Vandeputte","year":"2021","unstructured":"Vandeputte, M. M. et al. Chemical Characterization, and \u00b5-Opioid receptor activity assessment of the emerging group of nitazene 2-Benzylbenzimidazole synthetic opioids. ACS Chem. Neurosci. 12, 1241\u20131251 (2021). Synthesis.","journal-title":"ACS Chem. Neurosci."},{"key":"35256_CR36","doi-asserted-by":"publisher","first-page":"116796","DOI":"10.1016\/j.jpba.2025.116796","volume":"260","author":"O Wache\u0142ko","year":"2025","unstructured":"Wache\u0142ko, O., Tusiewicz, K., Szpot, P. & Zawadzki, M. The UHPLC-MS\/MS method for the determination of 26 synthetic benzimidazole opioids (nitazene analogs) with isomers separation. J. Pharm. Biomed. Anal. 260, 116796 (2025).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"35256_CR37","doi-asserted-by":"publisher","unstructured":"Ferreira, C. F., Antunes, A. M. M., Gaspar, H. & Caldeira, M. J. N-desethyl isotonitazene in fake oxycodone tablets seized in portugal: the first notification in Europe. Forensic Chem. 100696 https:\/\/doi.org\/10.1016\/j.forc.2025.100696 (2025).","DOI":"10.1016\/j.forc.2025.100696"},{"key":"35256_CR38","doi-asserted-by":"publisher","first-page":"112207","DOI":"10.1016\/j.forsciint.2024.112207","volume":"364","author":"ML Taylor","year":"2024","unstructured":"Taylor, M. L., Turbett, G. R., Lee, J. & Sears, A. Forensic intelligence in Australia and new zealand: status and future directions. Forensic Sci. Int. 364, 112207 (2024).","journal-title":"Forensic Sci. Int."},{"key":"35256_CR39","unstructured":"Krotulski, A. J. & Logan, B. K. NPS Discovery \u2013 Evolution of an Open- Access Drug Early Warning System. at (2021). https:\/\/www.cfsre.org\/images\/Krotulski_NPS_Discovery_Evolution_of_OA_EWS_111121AK.pdf"},{"key":"35256_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/1742-6723.13839","volume":"34","author":"JL Smith","year":"2022","unstructured":"Smith, J. L. et al. The emerging drugs network of australia: A toxicosurveillance system of illicit and emerging drugs in the emergency department. Emerg. Med. Australasia. 34, 58\u201364 (2022).","journal-title":"Emerg. Med. Australasia"},{"key":"35256_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/1742-6723.14059","volume":"35","author":"R Syrjanen","year":"2023","unstructured":"Syrjanen, R. et al. The emerging drugs network of Australia \u2013 Victoria clinical registry: A state-wide illicit substance surveillance and alert network. Emerg. Med. Australasia. 35, 82\u201388 (2023).","journal-title":"Emerg. Med. Australasia"},{"key":"35256_CR42","doi-asserted-by":"crossref","unstructured":"Evans-Brown, M. & Sedefov, R. in New Psychoactive Substances (eds Maurer, H. H. & Brandt, S. D.) 252, 3\u201349, Springer International Publishing, (2018).","DOI":"10.1007\/164_2018_160"},{"key":"35256_CR43","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.toxac.2022.06.022","volume":"34","author":"Joanna","year":"2022","unstructured":"Joanna et al. New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU early warning system. Toxicol. Anal. Et Clinique. 34, S29\u2013S30 (2022).","journal-title":"Toxicol. Anal. Et Clinique"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35256-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:03:07Z","timestamp":1770411787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35256-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["35256"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-35256-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5163"}}